# A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa

> **NCT06891885** · PHASE1,PHASE2 · RECRUITING · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 12 (estimated)

## Conditions studied

- Retinitis Pigmentosa

## Interventions

- **DRUG:** DSP-3077 Retinal Sheet Cohort 1
- **DRUG:** DSP-3077 Retinal Sheet Cohort 2
- **DRUG:** DSP-3077 Retinal Sheet Cohort 3

## Key facts

- **NCT ID:** NCT06891885
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-04-16
- **Primary completion:** 2028-10-31
- **Final completion:** 2032-10-31
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06891885

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06891885, "A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06891885. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*